In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Lineage Cell Therapeutics Inc (AMEX: LCTX) was $1.65 for the day, down -1.79% from the previous closing price of $1.68. In other words, the price has decreased by -$1.79 from its previous closing price. On the day, 0.72 million shares were traded. LCTX stock price reached its highest trading level at $1.68 during the session, while it also had its lowest trading level at $1.61.
Ratios:
Our analysis of LCTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4. On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5. On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 24 ’25 when DON M BAILEY bought 60,000 shares for $1.60 per share.
DON M BAILEY bought 80,000 shares of LCTX for $97,472 on Sep 10 ’25. On Jan 27 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the Director of the company, bought 7,894,737 shares for $0.76 each. As a result, the insider paid 6,000,000 and bolstered with 49,560,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 380040416 and an Enterprise Value of 340931424. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.12 while its Price-to-Book (P/B) ratio in mrq is 17.24. Its current Enterprise Value per Revenue stands at 31.521 whereas that against EBITDA is -17.326.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.74, which has changed by 2.3 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $2.09, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is -4.98%, while the 200-Day Moving Average is calculated to be 46.73%.
Shares Statistics:
LCTX traded an average of 1.88M shares per day over the past three months and 1404780 shares per day over the past ten days. A total of 230.33M shares are outstanding, with a floating share count of 217.61M. Insiders hold about 5.52% of the company’s shares, while institutions hold 44.98% stake in the company. Shares short for LCTX as of 1765756800 were 23708947 with a Short Ratio of 12.59, compared to 1763078400 on 22579627. Therefore, it implies a Short% of Shares Outstanding of 23708947 and a Short% of Float of 18.25.
Earnings Estimates
. The current rating of Lineage Cell Therapeutics Inc (LCTX) reflects the combined expertise of 6.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.02, with high estimates of $0.0 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.14 and -$0.42 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.06, with 6.0 analysts recommending between $0.03 and -$0.12.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $3.68M to a low estimate of -$1.75M. As of. The current estimate, Lineage Cell Therapeutics Inc’s year-ago sales were $2.87M
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $11.63M, while the lowest revenue estimate was $6.2M, resulting in an average revenue estimate of $9.9M. In the same quarter a year ago, actual revenue was $9.5M
